Authors: Nash, CL Panaccione, R Sutherland, LR Meddings, JB

Citation: Cl. Nash et al., Giant cell myocarditis, in a patient with Crohn's disease, treated with etanercept - a tumour necrosis factor-alpha antagonist, CAN J GASTR, 15(9), 2001, pp. 607-611

Authors: Panaccione, R Fedorak, RN Feagan, B Steinhart, H Wild, G Baron, D Bernstein, C Bitton, A Buckley, A Croitoru, K Enns, R Greenberg, G Hassard, P Semlacher, E Sutherland, L Tavenor, A Tourigny, M Walli, E Williams, N

Citation: R. Panaccione et al., Canadian Association of Gastroenterology clinical practice guidelines: Theuse of infliximab in Crohn's disease, CAN J GASTR, 15(6), 2001, pp. 367-370

Authors: Panaccione, R

Citation: R. Panaccione, Infliximab for the treatment of Crohn's disease: Review and indications for clinical use in Canada, CAN J GASTR, 15(6), 2001, pp. 371-375

Authors: Ricart, E Panaccione, R Loftus, EV Tremaine, WJ Sandborn, WJ

Citation: E. Ricart et al., Infliximab for Crohn's disease in clinical practice at the mayo clinic: The first 100 patients, AM J GASTRO, 96(3), 2001, pp. 722-729

Authors: Panaccione, R Gregor, JC Reynolds, RPE Preiksaitis, HG

Citation: R. Panaccione et al., Intrasphincteric botulinum toxin versus pneumatic dilatation for achalasia: a cost minimization analysis, GASTROIN EN, 50(4), 1999, pp. 492-498

Authors: Ricart, E Panaccione, R Loftus, EV Tremaine, WJ Sandborn, WJ

Citation: E. Ricart et al., Successful management of Crohn's disease of the ileoanal pouch with infliximab, GASTROENTY, 117(2), 1999, pp. 429-432